About this trial
CHIMOVIP is a study to determine the best therapeutic strategy in patient with ovarian advanced cancer.
Eligibility criteria
Qualifiers
Histologically confirmed advanced (FIGO stage III or IV) invasive epithelial ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer. Pleural cytology has to be performed in patients with pleural effusion.
Initial intervention : debulking surgery or diagnostic surgery in the 3 weeks before inclusion
Age ≥18 and < 75 years old.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 before surgery (ECOG ≤ 1 and Lee score < 6 in patients > 70 years old).
Disqualifiers
FIGO stage IV extra-abdominal disease, with the exception of lymph nodes and pleural invasion.
Patient having received previous chemotherapy for ovarian cancer.
Left ventricular ejection fraction < 50% before chemotherapy initiation
Other invasive cancer in the past 5 years (baso- and spinocellular cutaneous carcinoma with complete resection are accepted)
Trial design
Treatments tested in this trial
- CC0 - Carboplatin (IV) - Paclitaxel (IV)
- CC0 - Cisplatin (IP) - Epirubicin (IV)
- CC>0 - Carboplatin (IV)- Paclitaxel (IV)
- CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)
Treatment groups
Sponsors and collaborators
Groupe Hospitalier Diaconesses Croix Saint-Simon
Lead sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborator